Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

BACKGROUND AND OBJECTIVE: Pexidartinib is a novel oral small-molecule inhibitor that selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation. It is approved in the United S...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahir, Hamim, Greenberg, Jonathan, Shuster, Dale, Hsu, Ching, Watanabe, Kengo, LaCreta, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652259/
https://www.ncbi.nlm.nih.gov/pubmed/36264536
http://dx.doi.org/10.1007/s40262-022-01172-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652259/
https://www.ncbi.nlm.nih.gov/pubmed/36264536
http://dx.doi.org/10.1007/s40262-022-01172-9

Ejemplares similares